Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Sunday. The firm set a “buy” rating on the biotechnology company’s stock.

A number of other research firms have also recently weighed in on ADAP. Guggenheim decreased their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research report on Wednesday, March 26th. HC Wainwright decreased their price target on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Scotiabank dropped their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research note on Friday, March 21st. Finally, Wells Fargo & Company cut their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Adaptimmune Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $1.83.

Adaptimmune Therapeutics Stock Down 0.7 %

ADAP stock opened at $0.26 on Friday. The company has a market cap of $65.95 million, a price-to-earnings ratio of -1.17 and a beta of 2.84. The company has a fifty day moving average price of $0.47 and a 200 day moving average price of $0.63. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The business had revenue of $3.22 million during the quarter, compared to analysts’ expectations of $16.56 million. Sell-side analysts expect that Adaptimmune Therapeutics will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Two Seas Capital LP purchased a new position in Adaptimmune Therapeutics in the fourth quarter valued at about $7,992,000. Two Sigma Investments LP raised its holdings in shares of Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 19,146 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 58,787 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 152,780 shares during the period. Finally, Long Focus Capital Management LLC lifted its position in Adaptimmune Therapeutics by 54.1% during the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after buying an additional 7,194,503 shares during the period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.